ously determine whether MAVS is involved in TLR3 signaling.
The presence of megalin appears to be crucial for optimal internalization of sex steroid hormones and for access of the hormone to its cognate intracellular receptor in vitro. This appears to be true in vivo, at least temporally, as female mice that lack megalin show abnormalities in vaginal opening in response to estrogen, and megalin-deficient male mice exhibit defects in testicular descent in response to androgens. Both conditions are specific sex steroid-dependent events in the postnatal development of rodent genitalia. Simply increasing the amount of androgen in pregnant mice did not rescue the embryonic genital defects, indicating that free hormone was not able to compensate for the lack of megalin. However, the fact that megalin-deficient animals are not phenocopies of mice lacking androgen or estrogen receptors suggests that there must be megalin-independent pathways for the entry of sex steroids into target cells expressing the appropriate hormone receptor.
The classic dogma regarding sex steroid hormone entry into target cells is the "free" hormone hypothesis (see Figure 1, upper panel) . This hypothesis states that, by virtue of its small size and lipid solubility, only the "free" steroid hormone, which has escaped the grasp of its circulating serum binding protein, can traverse the plasma membrane of target cells. Once inside the cell, the steroid hormone must locate the intracellular protein with which it needs to interact. For example, the target protein for testosterone may be the androgen receptor, or it may be the enzyme 5α-reductase for which testosterone is the preferred substrate and dihydrotestosterone the product. The inability to efficiently deliver androgen to its cognate receptor or testosterone to the 5α-reductase will result in incomplete androgenization of the host and a phenotype not dissimilar from that exhibited by male mice deficient in megalin (Griffin et al., 1982) . However, as megalin-deficient animals are not completely resistant to androgens or estrogens, this suggests that either "free" hormone is somehow able to find its way to the androgen receptor or estrogen receptor, or that there exist other plasmamembrane receptors that promote the internalization of the steroid hormone. It is also possible, as suggested by Hammes total hormone present in the plasma or serum of the host constitute the biologically relevant form of the steroid that interacts with its intracellular receptor and regulates hormone-directed transcription? Current estimates are that 30% of American males in the 60-to 70-year-old age group and 70% of those in the 70-to 80-year-old age group have low serum bioavailable or "free'" testosterone levels (Hijazi and Cunningham, 2005) . If not at risk for androgen-promoted prostate or cardiovascular disease, should we consider male hormone replacement in such men a treatment that enhances muscle mass, strength, mood, and libido and treats osteopenia (low bone mass), osteoporosis, and erectile dysfunction, if their "free" testosterone is low? Although this field requires substantial further research, the results that Hammes et al. present here suggest that we may need to re-examine clinical decisions based on the extracellular concentration of "free" hormone. 
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